Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02842203 · ClinicalTrials.gov registry record

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

A clinical trial of Stage III Colorectal Cancer, sponsored by University of Pittsburgh.

Active
Registry status
137
Enrollment target
1
Study location

NCT02842203 is a study of Stage III Colorectal Cancer that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 137 participants, above the 61-participant average among 4 other Stage III Colorectal Cancer trials with a reported enrollment target (125% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02842203, a study of Stage III Colorectal Cancer, is active but no longer recruiting, sponsored by University of Pittsburgh.

ACTIVE NOT RECRUITING
Registry status
137 participants
Enrollment target
1
Study location

Study Summary

This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 137 participants
Start Date 2016-09
Est. Completion 2026-09

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT02842203

The ClinicalTrials.gov registry entry for NCT02842203 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 61-participant average among 4 other Stage III Colorectal Cancer trials with a reported enrollment target (125% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stage III Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02842203 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02842203 about?

NCT02842203 is a clinical study titled "Use of ctDNA for Monitoring of Stage III Colorectal Cancer". This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

What is the current status of trial NCT02842203?

This trial is currently active not recruiting. The enrollment target is 137 participants. The study started on 2016-09. Estimated completion is 2026-09.

What conditions does trial NCT02842203 study?

This clinical trial studies the following conditions: Stage III Colorectal Cancer.

Who is sponsoring clinical trial NCT02842203?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02842203 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.